An Analysis of the FALCON Trial

Matthew J. Ellis, MD, PhD, professor, Department of Medicine, Oncology Division, Breast Oncology Section, Washington University School of Medicine in St. Louis, Missouri and the Siteman Cancer Center, discusses the ongoing phase III FALCON trial.

Clinical Pearls

• The FALCON trial is comparing anastrozole to the newly approved, high-dose fulvestrant (500mg) for patients with treatment-naïve metastatic breast cancer
• The rationale of the trial is to see if the high dose of fulvestrant will maintain disease control for a longer period of time than patients receiving anastrozole
• This is a registration trial and will alter the label of fulvestrant to include treatment-naïve advanced breast cancer